Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564246 | 1.00 | REN (0.49) | RENMETAP2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12991841 | 0.84 | REN (0.49) | REN | |
| SCHEMBL8826775 | 0.82 | REN (0.70) | RENMETAP2 | |
| SCHEMBL3564204 | 0.81 | REN (0.68) | RENMETAP2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12991516 | 0.80 | REN (0.42) | RENMETAP2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12990972 | 0.80 | REN (0.42) | RENMETAP2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3565755 | 0.79 | REN (0.39) | RENMETAP2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3565758 | 0.79 | REN (0.39) | RENMETAP2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7268424 | 0.77 | REN (0.41) | RENMETAP2 | |
| SCHEMBL27835100 | 0.77 | METAP2 (0.70) | RENMETAP2CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858624-B2 | Piperidine and morpholine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264432-A1 | Piperidine and Morpholine Renin Inhibitors | REN, ACE, PREP | REN 1/4885METAP2 35/4885CHRNB2 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.